BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Ceritinib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Ceritinib\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT02321501-1967@assetmemo.bio
DTSTAMP:20261121T004054Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Ceritinib: Phase 1 readout est. (NCT02321501)
DESCRIPTION:Ceritinib\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: Cerit
 inib and Everolimus in Treating Patients With Locally Advanced or Metastat
 ic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer\nEstimated pri
 mary completion: 31 December 2026. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/ceritinib#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT02321501
URL:https://assetmemo.bio/drug/ceritinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02393625-1967@assetmemo.bio
DTSTAMP:20261121T004054Z
DTSTART;VALUE=DATE:20270409
DTEND;VALUE=DATE:20270410
SUMMARY:Ceritinib: Phase 1 readout est. (NCT02393625)
DESCRIPTION:Ceritinib\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: Study
  of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Pati
 ents With ALK-positive Non-small Cell Lung Cancer\nEstimated primary compl
 etion: 9 April 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 ceritinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT02393625
URL:https://assetmemo.bio/drug/ceritinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02584933-1967@assetmemo.bio
DTSTAMP:20261121T004054Z
DTSTART;VALUE=DATE:20270609
DTEND;VALUE=DATE:20270610
SUMMARY:Ceritinib: Phase 4 readout est. (NCT02584933)
DESCRIPTION:Ceritinib\, phase 4.\nStudy: Roll-over Study to Allow Access to
  Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novart
 is-sponsored Study\nEstimated primary completion: 9 June 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/ceritinib#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT02584933
URL:https://assetmemo.bio/drug/ceritinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06813079-1967@assetmemo.bio
DTSTAMP:20261121T004054Z
DTSTART;VALUE=DATE:20280217
DTEND;VALUE=DATE:20280218
SUMMARY:Ceritinib: Phase 2 readout est. (NCT06813079)
DESCRIPTION:Ceritinib\, phase 2.\nStudy: Using Tumor Models to Determine Tr
 eatments\nEstimated primary completion: 17 February 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/ceritinib#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06813079
URL:https://assetmemo.bio/drug/ceritinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02559778-1967@assetmemo.bio
DTSTAMP:20261121T004054Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Ceritinib: Phase 2 readout est. (NCT02559778)
DESCRIPTION:Ceritinib\, phase 2.\nStudy: Pediatric Precision Laboratory Adv
 anced Neuroblastoma Therapy\nEstimated primary completion: September 2030.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/ceritinib#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT02559778
URL:https://assetmemo.bio/drug/ceritinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07893197-1967@assetmemo.bio
DTSTAMP:20261121T004054Z
DTSTART;VALUE=DATE:20310131
DTEND;VALUE=DATE:20310201
SUMMARY:Ceritinib: Phase 2 readout est. (NCT07893197)
DESCRIPTION:Ceritinib\, phase 2.\nStudy: Ceritinib Treatment for Recurrent 
 Meningiomas\nEstimated primary completion: January 2031. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/ceritinib#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07893197
URL:https://assetmemo.bio/drug/ceritinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
